LONZA N | 582.40 / +1.50% |
Date/Time | 03/01 / 09:10 |
Chg. / Chg.(%) | 8.60 / +1.50% |
Bid | 582.00 / 146 |
Ask | 582.40 / 18 |
Open | 581.80 |
Previous Close | 573.80 |
High | 583.60 |
Low | 579.60 |
Volume [CHF] | 4,381,012.50 |
Volume [Units] | 7,527 |
Price fixings | 310 |
ISIN | CH0013841017 |
Security | LONN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 582.40 | ![]() |
7,527 |
Cboe Europe .. | 581.00 | ![]() |
478 |
London Inter.. | 580.20 | ![]() |
383 |
Cboe Europe .. | 581.00 | ![]() |
299 |
Turquoise | 581.80 | ![]() |
36 |
Lang & Schwa.. | 526.400 | ![]() |
|
Nasdaq Other.. | 631.1300 | ![]() |
401 |
Mexico | 13,449.09 | ![]() |
290 |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Recro Announces Executive Changes
12/16/2020 / 13:00 - GlobeNewswire - Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
12/07/2020 / 22:05 - GlobeNewswire